Diabetes: Page 4
-
Mario Tama via Getty Images
Drilling down on obesity drugs: What medtech executives are saying
Investor concerns that interest in GLP-1s will slow demand for medical devices and procedures have shaved roughly $370 billion in value from stocks across the medtech sector, according to research by Mizuho.
By Susan Kelly • Nov. 2, 2023 -
zirconicusso via Getty Images
GE HealthCare’s imaging AI will become ‘increasingly meaningful’ to growth: Moody’s
Even if modestly accretive, AI could support longer-term revenue targets at GE HealthCare and its competitors, Moody’s analysts wrote.
By Nick Paul Taylor • Oct. 27, 2023 -
peakSTOCK via Getty Images
GE HealthCare, Novo Nordisk partner to use ultrasound to treat diabetes, obesity
The collaborators will study the use of peripheral focused ultrasound as a non-invasive, non-pharmacological method of managing blood glucose.
By Nick Paul Taylor • Oct. 25, 2023 -
Courtesy of Insulet Corp.
Insulet receives FDA clearance for Omnipod 5 iPhone app
The application removes the need for patients with iPhones to carry a separate controller to manage bolus dosing.
By Elise Reuter • Oct. 23, 2023 -
Courtesy of Abbott
Abbott raises outlook amid strong Q3, sees momentum into 2024
Sales of the FreeStyle Libre continuous glucose monitor rose nearly 31% despite investor worries about the potential impact of weight-loss drugs on demand.
By Susan Kelly • Oct. 18, 2023 -
Sarah Silbiger via Getty Images
Boston Scientific wins diabetic neuropathy approval, joining rivals in growing market
The expanded indication positions Boston Scientific to challenge Abbott, Medtronic and Nevro for the emerging opportunity in spinal cord stimulation to treat the condition.
By Nick Paul Taylor • Oct. 12, 2023 -
Daphne Howland/MedTech Dive
Best Buy to sell continuous glucose monitoring systems
It’s the tech retailer’s first foray into prescription-based medical device sales.
By Rebecca Pifer • Oct. 9, 2023 -
Permission granted by Insulet
Insulet CFO leaves for 3M health spinoff
Wayde McMillan is the second high-profile medtech executive in recent months to join 3M.
By Elise Reuter • Oct. 4, 2023 -
Permission granted by Abbott
Abbott data suggests GLP-1 drugs a ‘modest accelerator’ for CGMs: analysts
The analysis of U.S. insurance claims found people on GLP-1 therapy wear their FreeStyle Libre sensors more.
By Nick Paul Taylor • Sept. 29, 2023 -
Sarah Silbiger via Getty Images
Intarcia’s diabetes drug-device combo voted down again by FDA panel
The 19-member advisory committee unanimously voted against Intarcia in the review, citing cardiovascular and kidney safety concerns.
By Gwendolyn Wu • Sept. 25, 2023 -
Courtesy of Medtronic
Medtronic receives CE mark for CGM sensor, boosting challenge to Abbott and Dexcom
Medtronic has made the sensor smaller and eliminated the need for fingersticks to calibrate the device, bringing a challenger to market leaders Abbott and Dexcom.
By Nick Paul Taylor • Sept. 25, 2023 -
Permission granted by Bigfoot Biomedical
Q&ABigfoot CEO talks Abbott acquisition, future of diabetes tech
Jeffrey Brewer hopes to see more integrated solutions for people with diabetes, starting with the company’s partnership with Abbott.
By Elise Reuter • Sept. 15, 2023 -
dzika_mrowka via Getty Images
Insulin pump-makers grapple with questions about GLP-1s
The new class of weight loss drugs has caused a stock selloff, but is unlikely to “meaningfully change the long-term outlook for diabetes,” analysts wrote.
By Elise Reuter • Sept. 14, 2023 -
Courtesy of U.S. Food and Drug Administration
FDA proposes 3 guidances to improve 510(k) clearance process
The agency has made recommendations for selecting predicate devices, using clinical data and conducting performance testing for implants.
By Nick Paul Taylor • Sept. 7, 2023 -
Permission granted by Bigfoot Biomedical
Abbott to buy smart insulin pen cap maker Bigfoot
The planned acquisition could shift patients interested in smart pens to Abbott’s Libre CGMs, an analyst wrote.
By Elise Reuter • Sept. 6, 2023 -
Courtesy of Medtronic
Medtronic sued for allegedly sharing ‘treasure trove’ of diabetes patient data with Google
The plaintiff said disclosures to Google are “particularly problematic” because his use of Gmail meant his personal information was “automatically linked to his real identity.”
By Nick Paul Taylor • Sept. 5, 2023 -
Courtesy of Beta Bionics
Beta Bionics raises $100M to challenge Medtronic, Tandem for automated insulin dosing market
The company’s iLet Bionic Pancreas automates insulin dosing without requiring mealtime carb counting.
By Nick Paul Taylor • Sept. 1, 2023 -
Ethan Miller via Getty Images
Deep DiveWhy medtech firms are putting diabetes tech in consumer devices
As Abbott develops a line of wearable wellness devices, and Dexcom makes a CGM for people with diabetes who don’t take insulin, both companies are turning to new users for future growth.
By Elise Reuter • Updated Aug. 31, 2023 -
Medtronic raises earnings forecast amid supply chain, diabetes business improvements
The company also shared an update on the planned divestment of its monitoring and respiratory interventions segments.
By Elise Reuter • Aug. 22, 2023 -
Courtesy of Tandem
Tandem’s chief commercial officer to resign ahead of insulin pump rollout
Brian Hansen is stepping down as Tandem prepares to roll out its new Mobi pump.
By Elise Reuter • Aug. 21, 2023 -
Courtesy of Dexcom
Deep DiveDexcom, Abbott ramp up DTC marketing amid fight for share of growing diabetes market
As insurers cover continuous glucose monitors for more people, device-makers are taking a page from the pharma marketing playbook.
By Elise Reuter • Aug. 17, 2023 -
Courtesy of Insulet Corp.
Insulet claims EOFlow copied patch-pump design in patent suit
Insulet filed the lawsuit as competitor Medtronic plans to buy EOFlow for $738 million.
By Elise Reuter • Aug. 15, 2023 -
Permission granted by Senseonics
Senseonics seeks iCGM designation for implantable glucose monitor
The company also plans to submit results of a pivotal trial for a version of its device that can be worn for a year.
By Elise Reuter • Aug. 11, 2023 -
Douglas Cliff via Getty Images
Device volumes to hold up against threat of Wegovy, other GLP-1 drugs: analysts
Issues such as “nontrivial side effects, cost concerns and patient persistence” will mean physicians continue to use medical devices, analysts say.
By Nick Paul Taylor • Aug. 9, 2023 -
Courtesy of Dexcom
Dexcom hails CGM share gains as driver of 25% revenue growth in Q2
International market share gains and expanding coverage in the U.S. led the CGM maker to raise its revenue forecast for 2023.
By Nick Paul Taylor • July 28, 2023
Previous
